ReviewAnnals of oncology : official journal of the European Society for Medical Oncology2020
Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network.
Review in Annals of oncology : official journal of the European Society for Medical Oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 5 syntheses or guidelines pooled it, 142 citations in OpenAlex.
- Pooled it
- Diagnosis and Therapy of Soft Tissue Sarcomas: Spanish Group for Research in Sarcomas (GEIS) Guidelines.Cancers · 2025Guideline
- UK guidelines for the management of soft tissue sarcomas.British journal of cancer · 2025Guideline
- SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Guideline
- Systematic review of NTRK 1/2/3 fusion prevalence pan-cancer and across solid tumours.Scientific reports · 2023Pooled it
- Applicability of pan-TRK immunohistochemistry for identification of NTRK fusions in lung carcinoma.Scientific reports · 2021Trial
- Precision therapeutic strategies for advanced gastrointestinal stromal tumors.Cancer metastasis reviews · 2026Review
- Advances and Challenges in the Multidisciplinary Treatment of Retroperitoneal Infantile Fibrosarcoma in Early Life.European journal of haematology · 2026Article
- Not all NTRK fusions in mesenchymal neoplasia are driver events: implications on classification and targeted therapy.The journal of pathology. Clinical research · 2026Article
- High-Grade Endometrial Stromal Sarcoma withJournal of clinical medicine · 2026Article
- STRN::NTRK3-fused neoplasm with "monster cells" in the pelvis of a young adult female: expanding the clinicopathologic spectrum of NTRK-rearranged neoplasms.Virchows Archiv : an international journal of pathology · 2026Article
- Soft Tissue Sarcoma Burden and Research Productivity: Global Patterns and Disparities, 1990-2021.Health science reports · 2026Article
- Rapid screening of potent and mechanistically insightful repurposable anticancer drugs targeting EGFR for non-small cell lung cancer: machine learning-aided and structure-guided approach.Molecular diversity · 2026Article
- Review
- Neoadjuvant TRK inhibitors versus chemotherapy in advanced NTRK fusion-positive sarcomas: a real-world evidence analysis.The oncologist · 2026Article
- Performance and clinical utility of two targeted multigene panels for GIST molecular characterization.Scientific reports · 2025Article
- Assessing targetable NTRK1/2/3 fusions in mesenchymal tumors via whole-exome RNA sequencing.ESMO open · 2025Article
- A practical approach to better identify NTRK 1-3 fusion-positive mesenchymal neoplasms by pan-Trk immunohistochemistry.Virchows Archiv : an international journal of pathology · 2025Article
- Current management of neurotrophic receptor tyrosine kinase fusion-positive sarcoma: an updated review.Japanese journal of clinical oncology · 2025Review
- A case of quadruple wild-type gastrointestinal stromal tumor with CDC42BPB::NTRK3 fusion and abundant lymphoid infiltration.Diagnostic pathology · 2025Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
48 authors at 20 institutions in 17 countries.
Funding
Abstract
Sarcomas are a heterogeneous group of malignancies with mesenchymal lineage differentiation. The discovery of neurotrophic tyrosine receptor kinase (NTRK) gene fusions as tissue-agnostic oncogenic drivers has led to new personalized therapies for a subset of patients with sarcoma in the form of tropomyosin receptor kinase (TRK) inhibitors. NTRK gene rearrangements and fusion transcripts can be detected with different molecular pathology techniques, while TRK protein expression can be demonstrated with immunohistochemistry. The rarity and diagnostic complexity of NTRK gene fusions raise a number of questions and challenges for clinicians. To address these challenges, the World Sarcoma Network convened two meetings of expert adult oncologists and pathologists and subsequently developed this article to provide practical guidance on the management of patients with sarcoma harboring NTRK gene fusions. We propose a diagnostic strategy that considers disease stage and histologic and molecular subtypes to facilitate routine testing for TRK expression and subsequent testing for NTRK gene fusions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.